semaj83/ctmatch_classification huggingface dataset:
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 21.0-40.0,  Intestinal Permeability Challenge Test Intestinal Health Inflammation Healthy as assessed by the health and lifestyle questionnaire, (P9067 F02; in Dutch) physical examination results of the pre-study laboratory tests Males, Age >= 21 and <= 40 years at Day 01 of the study Body Mass Index (BMI) >= 20 and < 33 kg/m2. Preferably in high and low body fat mass ranges as to be determined by waist circumference Normal Dutch eating habits as assessed by P9067 F02 Voluntary participation Having given written informed consent Willing to comply with the study procedures, including the ETEC challenge  Subjects with one or more of the following characteristics will be excluded from participation Participation in any clinical trial including blood sampling and/or administration of substances up to 90 days before Day 01 of this study Participation in any non-invasive clinical trial up to 30 days before Day 01 of this study, including no blood sampling and/or oral, intravenous, inhalatory administration of substances Having a history of medical or surgical events that may significantly affect the study outcome, including gastrointestinal illness or surgical operations Use of antibiotics, immunosuppressive drugs, antacids, laxatives or anti-diarrhoeal drugs in the last 3 months before the study Alcohol consumption > 28 units/week for males Reported unexplained weight loss or gain of > 2 kg in the month prior to the pre-study screening Reported slimming or medically prescribed diet Reported vegan, vegetarian or macrobiotic Not willing to be off working as a food handler, in child care or as a healthcare worker with direct patient contact during the week of ETEC contamination
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 0.0-5.0,  Infections, Rotavirus A male or female child aged < 5 years at the time of admission. A child becomes ineligible on the day of her/his fifth birthday A subject, who during the study period Is hospitalised for acute gastroenteritis Or Visits an emergency room for acute gastroenteritis Or Has rotavirus positive laboratory results and develops acute gastroenteritis at least 48 hours after hospitalisation
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 0.25-13.0,  Kerosene Pneumonitis Ingestion in the preceding 24 hours Presence of respiratory symptoms and/or signs at presentation Informed consent obtained from parent or legal guardian Resident within the Red Cross Hospital drainage area and able to come for two follow-up appointments  Asymptomatic and no clinical signs Too ill to be excluded from receiving an antibiotic as judged by Requiring more than 2L/min nasal-prong oxygen Requiring continuous or intermittent positive airway pressure ventilation Fever > 40˚C Needing an antibiotic for another reason e.g. otitis media, tonsillitis Current antibiotic use, prior to kerosene ingestion Allergic to amoxicillin
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Diarrhea Accepting to participate and willing to deliver 2 stool samples With diarrhea: the first 10 children and 10 adults presenting each month at the health facility Without diarrhea: In Bissau matched controls drawn from the registration system at Bandim Health Project. In Finland controls selected at the health facilities participating  Not willing or able to deliver the stool samples
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 0.5-6.0,  Fever male and female children aged 06 months to 06 years old, weight above 5 kilo and axillary temperature above 37,5 celsius degree  patients with a bad general heath state patients with neoplasia, pepic ulcer, gastrointestinal bleeding,history of fever convulsion intolerant to dypirone, ibuprofen, acetaminophen or any other nonsteroidal antiinflammatory drug moderated or severe dehydration conscience state alteration not capable of ingest oral drugs patients being treated with steroids patients treated with antiinflammatory, analgesic and antipyretic drugs in the last 06 hours before the study
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Blastocystis Hominis Infections ≥ 18 years Gastrointestinal symptoms for more than 10 days B. hominis in any quantity in at least one stool specimen out of 3 examined No other pathogenic micro-organism identified  Fever > 37.5° bloody diarrhoea weight loss > 10% of usual body weight significant decrease of general condition oncological diseases immune deficiencies known chronic intestinal diseases use of anti-protozoan drugs in the last 2 weeks use of anti-coagulant treatment or antabuse pregnant and lactating women
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 4.0-21.0,  Sickle Cell Anemia Acute Chest Syndrome Hemoglobin SS, SC, SB0thal or SBthal Ages ≥ 4-21 years old Patients are admitted to the hematology oncology inpatient service and have been enrolled and consented in the study Meet clinical for ACS an infiltrate on Chest X-ray and one of the following Respiratory symptoms/signs (patients pulse oximetry < 92% or oxygen saturation < 2% below their baseline, tachypnea, cough, and increased work of breathing) Fever Chest pain AND Patients' eligible for a simple transfusion based on one of the following Hypoxemia (patients pulse oximetry < 92% or oxygen saturation < 2% below their baseline) Hemoglobin < 5 gm/dl Increased work of breathing  Patient requires exchange transfusion within first 24 hours of admission Patient requires PCCU transfer within first 24 hours of admission Hemoglobin > 9gm/dl secondary to these patients requiring an exchange transfusion
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Pulmonary Disease, Chronic Obstructive Signed and dated written informed consent Male or females ≥ 40 years of age Females must be post-menopausal or using a highly effective method for avoidance of pregnancy Established clinical history of COPD by ATS/ERS definition Post-albuterol spirometry FEV1/FVC ratio ≤ 0.70 and FEV1 ≥30 to ≤ 70% of predicted normal (NHANES III) Former or current smoker ≥10 pack years A history of diagnosed cardiovascular disease or a prior cardiovascular event including any of the following Established (i.e., by clinical signs or imaging studies) coronary artery disease (CAD) Established (i.e., by clinical signs or imaging studies) peripheral vascular (i.e., arterial) disease (PVD) Previous stroke  Current diagnosis of asthma Subjects with other respiratory disorders including α1-antitrypsin deficiency as the underlying cause of COPD, active tuberculosis, lung cancer, bronchiectasis (Note: focal bronchiectasis is not exclusionary), sarcoidosis, pulmonary fibrosis (Note: focal fibrotic pulmonary lesions are not exclusionary), pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases Lung volume reduction surgery within previous 12 months Clinically significant abnormalities not due to COPD by chest X-ray or CT scan Hospitalized for poorly controlled COPD within 12 weeks of Screening Poorly controlled COPD 6 weeks prior to Screening, defined as acute worsening of COPD that is managed by the subject with corticosteroids or antibiotics or that requires treatment prescribed by a physician Lower respiratory infection requiring antibiotics 6 weeks prior to Screening A moderate or severe COPD exacerbation and/or a lower respiratory tract infection (including pnuemonia) during the Run-In Period An abnormal, clinically significant finding in any liver chemistry, biochemical, or haematology tests at Screening (Visit 1) or upon repeat prior to randomization An abnormal, clinically significant ECG finding at Screening (Visit 1) or upon repeat prior to randomization
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 40.0-75.0,  Lung Cancer ages 40-75 years If ages 40-59, then one of the following needs to be met Current or ex-smoker with >25 pack years and a family history of lung cancer(parent or sibling) OR current or ex-smoker with > 25 pack years and COPD OR current or ex-smoker with a > 35 pack year history If ages 60-75, then one of the following additional needs to be met Current or ex-smoker with >25 pack years and a family history of lung cancer (parent or sibling) OR Current or ex-smoker with >25 pack years and COPD OR Current or ex-smoker with a >30 pack year history Subject is able to return to Cleveland Clinic for annual follow-up screening  Current health requires oxygen Have had a chest x-ray or CT of the chest within the last 6 months Previous pneumonectomy Lobectomy of the lung within the last 5 years Diagnosed malignancy within the last 5 years, excluding non-melanoma skin cancer, carcinoma in situ of the cervix and localized prostate cancer A medical condition that would prevent treatment for lung cancer Within the last 6 weeks, one of the following has occured A new cough or chronic cough that has gotten worse Either new shortness of breath, or any worsening of shortness of breath A cough producing blood
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection Men / Women aged 18 and over (We will also those adults who lack mental capacity for whom we have a legal representative) Successful treatment of clinically diagnosed CDAD using standard therapy (metronidazole or vancomycin given according to standard local hospital guidelines)  Woman of child bearing potential and not willing to use at least one highly effective contraceptive method throughout the study Male with spouse/partner of child bearing potential and not willing to use condoms Pregnant or breast feeding Unable to swallow tablets Life expectancy of <4 weeks Hypersensitivity to the active substance, to any rifamycin (e.g. rifampicin or rifabutin) or to any of its excipients (Tablet core: Sodium starch glycolate type A, glycerol distearate, colloidal anhydrous, silica, talc and microcrystalline cellulose. Tablet coating: hypromellose, titanium dioxide (E171), disodium edentate, propylene glycol and red iron oxide E172) >5 days post standard therapy (metronidazole or vancomycin) for clinically diagnosed CDAD
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 1.0-10.0,  Pneumonia children aged 1-10 y presenting to the emergency department must fulfil definition of 'pneumonia', ie any one of fever in the ED a recorded fever at home in the 48h prior to presentation, or WBC > 12 or WBC < 5 in the ED any one of tachypnoea on exam cough on exam or by history increased work of breathing on exam; or  or more episodes of emesis in the emergency history of CF, anatomic lung disease, bronchiectasis, congenital heart disease, repeated aspirations, malignancy, immune suppression, recent prolonged admission to hospital, pneumonia diagnosed within the last month, lung abscess within the past six months, > 24 hours of beta-lactam antibiotic therapy prior to presentation, allergy to penicillin, allergy to food colouring evidence of empyaema or necrotizing pneumonia on chest radiograph
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infectious Keratitis Subjects must be 18 years of age or older Ability to provide written informed consent Likely to complete all study visits Subjects must have one eye that with a diagnosis of infectious keratitis  A corneal perforation Descemetocele Pregnancy or breastfeeding Active Herpes corneal disease Patient is unwilling or unable to comply with a medication regimen and follow up appointments
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Community Acquired Pneumonia age ≥ 18 infiltrate on chest X-ray further cough or production of purulent sputum or pathologic lung auscultation (crackles) or fever  hospital inpatient treatment within the last 28 days Immune suppressed patients
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cough Dyspnea Wheezing Presenting to the Emergency Department with cough, wheezing and/or dyspnea (shortness of breath) Referred for CXR and/or CT scan  Life threatening medical condition requiring immediate treatment Unable to sit up for a chest ultrasound Unable to consent Pregnant Unable to speak, read and write in English
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 0.5-10.0,  Community-acquired Pneumonia Children aged 6 months to 10 years presenting with CAP will be eligible. CAP will be defined if all of the four following numeric are met fever (>37.5 C axillary, > 37.7 C oral, or >38 C rectal) recorded in the ED or at home in the 48h prior to presentation any one of tachypnoea on exam (>60 bpm for age <1 y, >50 bpm for 1-2 y of age, >40 bpm for 2-4 y of age, and >30 bpm for >4 y of age) cough on exam or by history increased work of breathing on exam; or auscultatory findings (focal crackles, bronchial breathing, etc.) consistent with pneumonia infiltrates on chest radiograph consistent with bacterial CAP as judged by the ED physician; and the attending ED physician diagnoses the child with primary CAP. (Children treated with systemic steroids in the ED will be presumed to have primary asthma exacerbation with possible infection and therefore will not meet criteria.) Participants must be well enough to be treated as outpatients (discharged home by the ED physician, adequate volume status, able to tolerate oral medication, oxygen saturation > 90%, no evidence of impending respiratory failure), and have no evidence of empyaema or necrotizing pneumonia on chest radiograph  Children will be excluded if they have any of the following: cystic fibrosis, anatomic lung disease, bronchiectasis, congenital heart disease, history of repeated aspiration or velopharyngeal incompetence, malignancy, conditions requiring treatment with immune suppressants, primary immunodeficiency, advanced HIV infection, prolonged admissions (>48 h) to hospital within the past 2 months, pneumonia previously diagnosed within the past month, lung abscess diagnosed within the past six months, receipt of > 24 hours of beta-lactam antibiotic therapy already received at presentation to the ED, receipt of at least a 5 day course of amoxicillin < 72h prior to presenting to the ED, receipt of an intravenous cephalosporin or azithromycin in the ED, or suspected allergy to penicillin. Children will not be eligible to participate more than once
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Rheumatic Dermatologic Disorders Informed Consent as documented by signature Indication for yellow fever vaccination according to Swiss FOPH recommendations Individuals under low dose MTX (≤20mg/week) therapy or healthy individuals Male and Female travelers ≥18 years to <60 years of age  Contraindications on ethical grounds Women who are pregnant or breast feeding Contraindication against yellow fever vaccination (e.g. hypersensitivity against vaccine ingredient) Current treatment with other immunosuppressive agent apart from low dose methotrexate Alemtuzumab or rituximab in the last year TNF-blocking therapy in past three months Immunocompromising condition in healthy control Other immunocompromising condition than MTX treatment itself and the underlying disease in patients under MTX Previous yellow fever vaccination No indication for yellow fever vaccination according to Swiss travel vaccination recommendations
Patient description: An 8-year-old male presents in March to the ER with fever up to 39 C, dyspnea and cough for 2 days. He has just returned from a 5 day vacation in Colorado. Parents report that prior to the onset of fever and cough, he had loose stools. He denies upper respiratory tract symptoms. On examination he is in respiratory distress and has bronchial respiratory sounds on the left. A chest x-ray shows bilateral lung infiltrates.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Typhoid Fever Subjects are male or female aged ≥ 18 years at time of dosing Subjects are travelers attending travelers' vaccination clinics Subjects are eligible for typhoid vaccination, according to standard practice Subjects are expected to be able to provide follow-up information Subjects have an expected travel departure date more than 21 days after enrollment (to enhance follow-up by ensuring subjects remain in the US during the AE collection period) Subjects must sign a written informed consent  Subjects with a known hypersensitivity to any component of the vaccine or the enteric coated capsule Subjects deficient in their ability to mount a humoral or cell-mediated immune response due to either a congenital or acquired immunodeficient state including treatment with immune-suppressive or antimitotic drugs Subjects with an acute febrile illness Subjects with acute gastrointestinal (GI) illness Subjects who are receiving medications with antibacterial activity (including proguanil) at the time of enrollment Subjects with other contraindications as determined by the site investigator